Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention

Background and aims The effect of dapagliflozin (DAPA) on the prognosis of patients with acute myocardial infarction (AMI) is unclear. The present study was conducted to evaluate the association between DAPA administration and adverse events in patients with AMI undergoing percutaneous coronary inte...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2022-09, Vol.21 (1), p.1-186, Article 186
Main Authors: Zhu, Yi, Zhang, Jia-li, Yan, Xue-jiao, Sun, Ling, Ji, Yuan, Wang, Fang-fang
Format: Article
Language:English
Subjects:
AIP
AMI
Angioplasty
Angiotensin
Antidiabetics
Blood pressure
Cardiac arrhythmia
Cardiovascular disease
Cerebral infarction
Congestive heart failure
Coronary vessels
DAPA
Diabetes
Diabetes mellitus
Ejection fraction
Electrocardiography
Fasting
Glucose
Heart attacks
Hematology
High density lipoprotein
Hospitals
Hypertension
Laboratories
MACE
Medical prognosis
Medical records
Myocardial infarction
Neprilysin
Plasma
Prognosis
Regression analysis
Survival analysis
TyG
Vein & artery diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and aims The effect of dapagliflozin (DAPA) on the prognosis of patients with acute myocardial infarction (AMI) is unclear. The present study was conducted to evaluate the association between DAPA administration and adverse events in patients with AMI undergoing percutaneous coronary intervention (PCI). Methods This single-center retrospective analysis study included a total of 786 patients with AMI from January 2019 to August 2021 who were or were not administered DAPA at discharge. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall deaths, heart failure, nonfatal MI, nonfatal stroke, and unplanned repeat revascularization (URR). Differences in the triglyceride glucose (TyG) index and the atherogenic index of plasma (AIP) both during hospitalization and 12 months after discharge (if achievable) were also compared. Results During a median follow-up of 23 months, 130 patients had MACE (118 in the DAPA-free group and 12 in the DAPA group). Kaplan–Meier survival analyses revealed that the cumulative incidence of MACE (log-rank test, p = 0.009), heart failure (p = 0.003), nonfatal MI (p = 0.005), and URR (p = 0.031) was higher in the DAPA-free group. In addition, the multivariate Cox analysis showed that DAPA was significantly associated with the reduced risk of MACE (hazard ratio = 0.170, 95% confidence interval = 0.078–0.373, p 
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-022-01627-0